



3 10/17/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paszty, et al.

Serial No.: 09/818,954

Group Art. Unit No.: 1647

Filed: March 27, 2001

Examiner: L. Spector, Ph.D.

For: BETA-LIKE GLYCOPROTEIN HORMONE
POLYPEPTIDE AND HETERODIMER

Docket No.: A-676B

TECH CENTER 1600/2900

OCT 22 2002

1647
#10
RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner. The relevance of each listed reference is discussed in the following paragraphs.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Scott N. Bernstein
Attorney/Agent for Applicant(s)
Registration No.: 38,827
Phone: (805) 447-4128
Date: October 15, 2002

Please send all future correspondence to:
US Patent Operations/ [SNB]
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL360691669US

Date of Deposit: October 15, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

St. St. Andrew
Printed Name

St. St. Andrew
Signature

Please send all future correspondence to:

US Patent Operations/ [SNB]
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799